ทิศทางโรคฮีโมฟีเลียในประเทศไทย

Bhanchet-Isarangkura P, Mahasandana C, Suvatte V, Hathirat P, Bintadish P, Sasanakul W, et al. Hemophilia in Thailand report of 164 cases. J Med Assoc Thai. 1978;61:72-7.

Isarangkura P, Bintadish P, Hathirat P, Sasanakul W, Watana-kasetr S, Thanamitra S. Study of the prevalence of hereditary bleeding disorders in Thailand. Vajira Med J. 1980;24:183-90.

Isarangkura PB, Pansatrenkul BJ. Hemophilia in developing countries-Thailand. WFH Bullatein. 1982;19:54-8.

National Policy on Blood Programme. Ministry of Health and National Blood Center of the Red Cross Society, Bangkok 1989.

Isarangkura P, Chuansumrit A. Developing and maintaining a hemophilia program in Thailand. In: Lusher JM, Kessler CM, editors. Hemophilia and von Willebrand’s Disease in the 1990s. New York, Elsevier Science Publishers. 1991:19-24.

Chuansumrit A, Pongtanakul B, Kadegasem P, Sasanakul W, Chotsupakarn S, Kitpoka P, Wongwerawattanakoon P, Bejrachandra S. Accurate bedside diagnostic kit for determining haemophilia A and B. Haemophilia. 2009;15(1):361-4.

Sasanakul W, Kadegasem P, Chaiyaratana W, Wongwerawattanakoon P, Sirachainan N, Chuansumrit A. Simple and accurate bedside diagnostic kit for determining haemophilia A and B: a revised version. Haemophilia. 2013;19(1):e48-9.

Srivastava A. Subcommittee on factor VIII, factor IX and rare coagulation disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions on hemophilia: communication from the SSC of the ISTH. J Thromb Hemost. 2014;12(11):1935-9.

Isarangkura P, Chuansumrit A, Panthangkura W, Hathirat P, Pandhawong S. Home therapy for hemophilia in Thailand. Southeast Asian J Trop Med Public Health. 1987;18:552-7.

Chuansumrit A, Isarangkura P, Chantanakajornfung A, Kuhathong K, Pintadit P, Jitpraphai C, et al. The efficacy and safety of lyophilized cryoprecipitate in hemophilia. J Med Assoc Thai. 1999;82(Suppl 1):S69-73.

Sooksriwong C, Boonkerd L, Chanjaruporn P, Chuansumrit A. Incremental cost effectiveness analysis for haemophilia homebased care programme in Thailand. Haemophilia. 2012;18:e347-63.

Pattanaprateep O, Chuansumrit A, Kongsakon R. Cost-utility analysis of home-based care for treatment of Thai hemophilia A and B. Value Health Reg Issues. 2014;3:73-8.

Nilsson IM, Berntorp E, Lofgvist T, Petersson H. Twenty-five years’ experience of prophylaxis treatment in severe hemophilia A and B. J Intern Med. 1992;232(1):25-32.

Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia. 2010;16(Suppl 5):181-8.

Chuansumrit A, Isarangkura P, Hathirat P. Prophylactic treatment for hemophilia A patient: a pilot study. Southeast Asian J Trop Med Public Health. 1995;26:243-6.

Chuansumrit A, Sosothikul D, Natesirinilkul R, Lektrakul Y, Charoenruangrit U, Factor VIII Study Group. Efficacy and safety of low-dose prophylaxis of highly purified plasma-derived factor VIII concentrate produced by the National Blood Centre, Thai Red Cross Society. Haemophilia. 2018;24(5):e387-90.

Gouider E. Show me the evidence: Effective low-dose prophylaxis. Haemophilia. 2019;26:9-10.

Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013;160(2):153-70.

Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;00:1-158. doi: 10.1111/ hae.14046

Oldenburg J, Mahalangu J, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-18.

George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, et al. Hemophilia B gene therapy with a high-specific- activity factor IX variant. N Engl J Med. 2017;377(23):2215-27.